Piper Sandler analyst Biren Amin raised the firm's price target on Aclaris Therapeutics to $11 from $7 and keeps an Overweight rating on the shares following the company's update ATI-052 & ATI-2138 last week. For ATI-052, the firm compared TARC data in Phase 1 healthy volunteers; TARC has the greatest evidence-based support of any AD biomarker for correlating with disease severity/therapeutic response. Comparing ATI-052's Phase 1 data to other Ab programs shows ATI-052 has a greater ability to decrease TARC vs Dupixent, Bambusa's BBT001, and Apogee's zumilokibart. ATI-052's safety profile is also devoid of ADAs which has readthrough to efficacy on longer-term dosing.
